CA-VELO3D
20.10.2020 15:02:11 CEST | Business Wire | Press release
VELO3D , an innovator in digital manufacturing, announced the expansion of its systems portfolio to include Sapphire XC, an “Extra Capacity” large-format printer that will increase production throughput by 5X and reduce cost-per-part by up to 75%, when compared to the existing Sapphire system.
The company also announced plans to roll-out Sapphire Gen 2, which will be a software and hardware upgrade to the current system. Users can expect an improvement of anywhere between 10-50% in productivity and part-cost metrics when compared to the current Sapphire system. The Sapphire Gen 2 upgrade will be available to retrofit on all installed systems starting in Q2 2021.
The Sapphire product family now includes Sapphire Gen 2, the 1-meter tall Sapphire 1MZ and Sapphire XC—all using the laser powder-bed fusion (LPBF) process with patented capabilities to print without consideration of support structures. Sapphire systems specifically address the aerospace, power generation, and energy markets' unmet needs for quality-assured manufacturing of uncompromised geometries.
"Printing larger parts without the additive manufacturing constraints of support structures is highly attractive to many industrial end-users,” said Benny Buller, founder, and CEO of VELO3D . “For the first time, customers will be able to 3D-print uncompromised geometries, with the highest confidence in part quality, in a large format system. Quality assurance with large scale components is critical because the economic impact of failed builds is very significant. We have demonstrated that our integrated solution is capable of producing a greater yield of high-quality parts, and that foundational technology will transfer to our new Sapphire XC."
Sapphire XC Features
- Larger build volume: Build volume 600mm x 550 mm (compared to 315mm x 400 mm in Sapphire)
- Higher productivity for production: 8 lasers x 1,000W each (compared to 2 lasers x 1,000W in Sapphire)
- Integrated manufacturing process: Fully integrated with Flow™ pre-print software and Assure™ quality control software
- Consistent architecture: Utilizes the same optical-train design, recoater technology, gas-flow technology, and metrology as the current Sapphire. Users can also expect similar material properties as Sapphire
- Qualified material alloys : Compatible alloys include Aluminum F357, Titanium 6AI-4V, INCONEL® 718 and HASTELLOY® X
Sapphire XC Pre-Order
Delivery of Sapphire XC will begin in Q4 2021. Early pre-order of Sapphire XC secures a price and an early manufacturing slot for the system. Existing orders of Sapphire XC will consume all available manufacturing slots for Q4 ’21 and most of Q1 ’22.
Webinar Invitation
To learn more about the value of the Sapphire XC large format system and how it addresses unmet customer needs, register for an informative online fireside chat on Oct 22nd at 10 a.m. Eastern Standard Time. Scott Dunham, Vice President of Research at Smartech Analysis will moderate a discussion with Benny Buller, founder and CEO of VELO3D . Live Q&A from the audience will be included in the webinar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005115/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom